omniture

Phase II Cystic Fibrosis Study Closes Enrollment

Pharmaxis Ltd
2007-03-02 12:12 735

SYDNEY, Australia, March 1 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) announced on Feb 23 that a Phase II clinical trial of Bronchitol in children with cystic fibrosis has closed its enrollment phase. The study is an independent investigator-initiated study being conducted at two sites in the United Kingdom.

The study has entered 25 subjects. The original target of 42 set by the investigator was revised downwards following a review of the trial and because of a shortage of volunteers at the two UK sites. Children enrolled in the trial are completing three months' treatment with each of three different therapies -- Bronchitol alone, both Bronchitol and Pulmozyme* together and Pulmozyme* alone. The trial will measure changes in lung function, airway inflammation, infections, and quality of life. The study is expected to conclude in 2008.

Pharmaxis Chief Executive Officer Alan Robertson said: "While not on the regulatory approval path, this is an important study for children with cystic fibrosis. Cystic fibrosis is a disease from birth and it is important to understand, as early as possible, how emerging therapies such as Bronchitol should be positioned in a patient's daily treatment regime. We look forward to the conclusion of the study."

A European, Pharmaxis sponsored, regulatory Phase III clinical trial, designed to lead to a marketing application for Bronchitol in adults and children with cystic fibrosis, has received the necessary approvals and is expected to commence recruitment shortly.

Approximately 75,000 people in the major world markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.

To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .

* Pulmozyme is a registered trademark of Genentech

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this press release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Virginia Nicholls

Tel: +61-0-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

CONTACT:

Alan Robertson - Chief Executive Officer

Tel: +61-2-9454-7200

Email: arobertson@pharmaxis.com.au

Source: Pharmaxis Ltd
collection